Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Cash & Equivalents (2016 - 2025)

Gsk has reported Cash & Equivalents over the past 11 years, most recently at $4.5 billion for Q4 2025.

  • Quarterly results put Cash & Equivalents at $4.5 billion for Q4 2025, down 9.03% from a year ago — trailing twelve months through Dec 2025 was $4.5 billion (down 9.03% YoY), and the annual figure for FY2025 was $4.5 billion, down 9.03%.
  • Cash & Equivalents for Q4 2025 was $4.5 billion at Gsk, down from $5.0 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for GLAXF hit a ceiling of $5.8 billion in Q4 2021 and a floor of $3.6 billion in Q4 2023.
  • Median Cash & Equivalents over the past 5 years was $4.5 billion (2025), compared with a mean of $4.7 billion.
  • Biggest five-year swings in Cash & Equivalents: tumbled 30.65% in 2021 and later soared 36.31% in 2024.
  • Gsk's Cash & Equivalents stood at $5.8 billion in 2021, then dropped by 24.21% to $4.4 billion in 2022, then dropped by 16.55% to $3.6 billion in 2023, then skyrocketed by 36.31% to $5.0 billion in 2024, then dropped by 9.03% to $4.5 billion in 2025.
  • The last three reported values for Cash & Equivalents were $4.5 billion (Q4 2025), $5.0 billion (Q4 2024), and $3.6 billion (Q4 2023) per Business Quant data.